docid|source|sourcetype|target|targettype|type
0|Bayesian Models And Decision Algorithms For Complex Early Phase Clinical Trials|Topic|Peter F. Thall|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Tianyu Zhan|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Yiwang Zhou|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Ziqian Geng|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Yihua Gu|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Jian Kang|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Li Wang|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Xiaohong Huang|Author|AUTHORED
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper|Elizabeth H. Slate|Author|AUTHORED
2|Pilot Studies Of Structured Treatment Interruptions In Hiv Therapy|Topic|Hiv Therapy|Topic|RELATED_TO
2|Hiv Therapy|Topic|Virologic Failure|Topic|RELATED_TO
2|Novel Hypothesis|Topic|Virologic Failure|Topic|DISCUSSES
2|Mathematical Model Of Hiv Within-Host Viral Dynamics|Topic|Nonlinear Parametric Resonance|Topic|DISCUSSES
2|Clinical Trial Data|Topic|Patient-Specific Resonant Spectra|Topic|DISCUSSES
2|Immunologic And Virologic Parameters|Topic|Patient-Specific Resonant Spectra|Topic|DISCUSSES
2|Romulus Breban|Author|Novel Hypothesis|Topic|AUTHORED
2|Sally Blower|Author|Novel Hypothesis|Topic|AUTHORED
3|Two-Phase Sampling|Topic|Immune Response Markers|Topic|RELATED_TO
3|Preventive Vaccines|Topic|Hiv|Topic|RELATED_TO
3|Txshift R Package|Topic|Nima S. Hejazi|Author|AUTHORED
3|Txshift R Package|Topic|Mark J. Van Der Laan|Author|AUTHORED
3|Txshift R Package|Topic|Holly E. Janes|Author|AUTHORED
3|Txshift R Package|Topic|Peter B. Gilbert|Author|AUTHORED
3|Txshift R Package|Topic|David C. Benkeser|Author|AUTHORED
4|Phase 1-2 Designs|Topic|Dose Finding|Topic|RELATED_TO
4|Phase 1-2 Designs|Topic|Clinical Response|Topic|RELATED_TO
4|Phase 1-2 Designs|Topic|Toxicity|Topic|RELATED_TO
4|Generalized Phase 1-2 Design|Topic|Candidate Doses|Topic|RELATED_TO
4|Generalized Phase 1-2 Design|Topic|Patients|Topic|RELATED_TO
4|Generalized Phase 1-2 Design|Topic|Long-Term Success Rate|Topic|RELATED_TO
4|Biological Outcome|Topic|Pharmacodynamic Activity|Topic|RELATED_TO
4|Biological Outcome|Topic|Immunological Effect|Topic|RELATED_TO
4|Multivariate Dose-Outcome Models|Topic|Clinical Outcomes|Topic|RELATED_TO
4|Bayesian Model Selection|Topic|Biologically Inactive Doses|Topic|RELATED_TO
4|Therapeutically Optimal Dose|Topic|Restricted Mean Survival Time|Topic|RELATED_TO
4|Simulation Study|Topic|Proposed Design|Topic|RELATED_TO
4|Demo|Paper|Cheng-Han Yang|Author|AUTHORED
4|Demo|Paper|Peter F. Thall|Author|AUTHORED
4|Demo|Paper|Ruitao Lin|Author|AUTHORED
5|Randomized Controlled Trials|Topic|Intercurrent Events|Topic|DISCUSSES
5|Immunology Trials|Topic|Intercurrent Events|Topic|DISCUSSES
5|Treatment-Related Intercurrent Events|Topic|Composite Variable Strategy|Topic|DISCUSSES
5|Treatment-Unrelated Intercurrent Events|Topic|Hypothetical Strategy|Topic|DISCUSSES
5|Causal Estimand|Topic|Doubly Robust Estimators|Topic|DISCUSSES
5|Baricitinib|Topic|Systemic Lupus Erythematosus|Topic|RELATED_TO
5|Sizhu Lu|Author|Estimating Treatment Effects With Competing Intercurrent Events In Randomized Controlled Trials|Paper|AUTHORED
5|Yanyao Yi|Author|Estimating Treatment Effects With Competing Intercurrent Events In Randomized Controlled Trials|Paper|AUTHORED
5|Yongming Qu|Author|Estimating Treatment Effects With Competing Intercurrent Events In Randomized Controlled Trials|Paper|AUTHORED
5|Huayu Karen Liu|Author|Estimating Treatment Effects With Competing Intercurrent Events In Randomized Controlled Trials|Paper|AUTHORED
5|Ting Ye|Author|Estimating Treatment Effects With Competing Intercurrent Events In Randomized Controlled Trials|Paper|AUTHORED
5|Peng Ding|Author|Estimating Treatment Effects With Competing Intercurrent Events In Randomized Controlled Trials|Paper|AUTHORED
6|Align|Topic|Large Language Models|Topic|RELATED_TO
6|Align|Topic|Anatomical Therapeutic Chemical|Topic|RELATED_TO
6|Align|Topic|Medical Dictionary For Regulatory Activities|Topic|RELATED_TO
6|Nabeel Seedat|Author|Align|Topic|AUTHORED
6|Caterina Tozzi|Author|Align|Topic|AUTHORED
6|Andrea Hita Ardiaca|Author|Align|Topic|AUTHORED
6|Mihaela Van Der Schaar|Author|Align|Topic|AUTHORED
6|James Weatherall|Author|Align|Topic|AUTHORED
6|Adam Taylor|Author|Align|Topic|AUTHORED
7|Ross M. Kedl|Author|An Immunological Autobiography|Paper|AUTHORED
7|An Immunological Autobiography|Paper|Sars-Cov2|Topic|DISCUSSES
7|An Immunological Autobiography|Paper|Moderna Phase Iii Clinical Trial|Topic|DISCUSSES
7|An Immunological Autobiography|Paper|Covid-19 Vaccine Trial|Topic|DISCUSSES
7|An Immunological Autobiography|Paper|Longitudinal Evaluation Of T And B Cell Immunity|Topic|DISCUSSES
8|Sleep Monitoring Algorithm|Topic|Hao He|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Chao Li|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Wolfgang Ganglberger|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Kaileigh Gallagher|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Rumen Hristov|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Michail Ouroutzoglou|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Haoqi Sun|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Jimeng Sun|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Brandon Westover|Author|AUTHORED
8|Sleep Monitoring Algorithm|Topic|Dina Katabi|Author|AUTHORED
9|Vaccine Efficacy Estimands|Topic|Immunological Effects|Topic|RELATED_TO
9|Vaccine Efficacy Estimands|Topic|Behavioral Effects|Topic|RELATED_TO
9|Mats Stensrud|Author|Vaccine Efficacy Estimands|Topic|AUTHORED
9|Daniel Nevo|Author|Vaccine Efficacy Estimands|Topic|AUTHORED
9|Uri Obolski|Author|Vaccine Efficacy Estimands|Topic|AUTHORED
9|Influenza Vaccine Trial|Topic|Vaccine Efficacy Estimands|Topic|RELATED_TO
9|Belief Variable|Topic|Vaccine Efficacy Estimands|Topic|RELATED_TO
9|Blinding Assessment|Topic|Belief Variable|Topic|RELATED_TO
9|Vaccine Trials|Topic|Vaccine Efficacy Estimands|Topic|RELATED_TO
10|Panacea|Topic|Trialalign|Topic|RELATED_TO
10|Panacea|Topic|Trialinstruct|Topic|RELATED_TO
10|Panacea|Topic|Trialpanorama|Topic|RELATED_TO
10|Panacea|Topic|Jiacheng Lin|Author|AUTHORED
10|Panacea|Topic|Hanwen Xu|Author|AUTHORED
10|Panacea|Topic|Zifeng Wang|Author|AUTHORED
10|Panacea|Topic|Sheng Wang|Author|AUTHORED
10|Panacea|Topic|Jimeng Sun|Author|AUTHORED
11|Immune Correlates Of Protection|Topic|Correlates Of Risk|Topic|RELATED_TO
11|Correlates Of Risk|Topic|Controlled Vaccine Efficacy Curve|Topic|RELATED_TO
11|Controlled Vaccine Efficacy Curve|Topic|Controlled-Risk Curve|Topic|RELATED_TO
11|Controlled Vaccine Efficacy Curve|Topic|50% Neutralizing Antibody Titer|Topic|RELATED_TO
11|50% Neutralizing Antibody Titer|Topic|Virologically Confirmed Dengue|Topic|RELATED_TO
11|Cyd14|Paper|Peter B. Gilbert|Author|AUTHORED
11|Cyd14|Paper|Youyi Fong|Author|AUTHORED
11|Cyd14|Paper|Marco Carone|Author|AUTHORED
11|Cyd15|Paper|Peter B. Gilbert|Author|AUTHORED
11|Cyd15|Paper|Youyi Fong|Author|AUTHORED
11|Cyd15|Paper|Marco Carone|Author|AUTHORED
13|Trial2Vec|Topic|Zifeng Wang|Author|AUTHORED
13|Trial2Vec|Topic|Jimeng Sun|Author|AUTHORED
13|Trial2Vec|Topic|Clinical Trials|Topic|DISCUSSES
13|Trial2Vec|Topic|Umls Knowledge Base|Topic|RELATED_TO
14|Spot|Topic|Clinical Trials|Topic|RELATED_TO
14|Zifeng Wang|Author|Spot|Topic|AUTHORED
14|Cao Xiao|Author|Spot|Topic|AUTHORED
14|Jimeng Sun|Author|Spot|Topic|AUTHORED
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Matrix-Valued Time-Series Data Clustering|Topic|DISCUSSES
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Low-Dimensional Embedding|Topic|DISCUSSES
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Static Clinical Covariates|Topic|DISCUSSES
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|High-Dimensional Longitudinal Features|Topic|DISCUSSES
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Sparse And Irregular Nature Of Sample Collection|Topic|DISCUSSES
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Intensive Simulations|Topic|DISCUSSES
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper|Immunological Data Set From Patients With Sars-Cov-2 Infection|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|World Health Organization|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Hiv Treatment|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Resource-Limited Settings|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Clinical And Immunological Markers|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Cd4 Cell Counts|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Viral Load|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Diagnostic Algorithm|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Miriam Hospital Immunology Clinic|Topic|DISCUSSES
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Tao Liu|Author|AUTHORED
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Joseph W. Hogan|Author|AUTHORED
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Lisa Wang|Author|AUTHORED
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Shangxuan Zhang|Author|AUTHORED
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper|Rami Kantor|Author|AUTHORED
17|Clinical Trials|Topic|Nlp|Topic|RELATED_TO
17|Eligibility Classification|Topic|Phase 3 Cancer Trials|Topic|RELATED_TO
17|Eligibility Classification|Topic|Non-Cancer Trials|Topic|RELATED_TO
17|Phase 3 Cancer Trials|Topic|Annotated Eligibility Criteria Dataset|Topic|RELATED_TO
17|Phase 1 And 2 Cancer Trials|Topic|Annotated Eligibility Criteria Dataset|Topic|RELATED_TO
17|Heart Disease Trials|Topic|Annotated Eligibility Criteria Dataset|Topic|RELATED_TO
17|Type 2 Diabetes Trials|Topic|Annotated Eligibility Criteria Dataset|Topic|RELATED_TO
17|Observational Trials|Topic|Annotated Eligibility Criteria Dataset|Topic|RELATED_TO
17|Yumeng Yang|Author|Exploring The Generalization Of Cancer Clinical Trial Eligibility Classifiers Across Diseases|Paper|AUTHORED
17|Ashley Gilliam|Author|Exploring The Generalization Of Cancer Clinical Trial Eligibility Classifiers Across Diseases|Paper|AUTHORED
17|Ethan B Ludmir|Author|Exploring The Generalization Of Cancer Clinical Trial Eligibility Classifiers Across Diseases|Paper|AUTHORED
17|Kirk Roberts|Author|Exploring The Generalization Of Cancer Clinical Trial Eligibility Classifiers Across Diseases|Paper|AUTHORED
17|Few-Shot Learning|Topic|Cross-Disease Generalization|Topic|RELATED_TO
18|Trialsynth|Topic|Chufan Gao|Author|AUTHORED
18|Trialsynth|Topic|Mandis Beigi|Author|AUTHORED
18|Trialsynth|Topic|Afrah Shafquat|Author|AUTHORED
18|Trialsynth|Topic|Jacob Aptekar|Author|AUTHORED
18|Trialsynth|Topic|Jimeng Sun|Author|AUTHORED
19|Ct-Bert|Topic|Named Entity Recognition (Ner) Models|Topic|DISCUSSES
19|Ct-Bert|Topic|Clinical Trial Nlp|Topic|DISCUSSES
19|Xiong Liu|Author|Ct-Bert|Topic|AUTHORED
19|Greg L. Hersch|Author|Ct-Bert|Topic|AUTHORED
19|Iya Khalil|Author|Ct-Bert|Topic|AUTHORED
19|Murthy Devarakonda|Author|Ct-Bert|Topic|AUTHORED
19|Ct-Bert|Topic|Attention-Based Bilstm|Topic|RELATED_TO
19|Ct-Bert|Topic|Criteria2Query|Topic|RELATED_TO
20|Ctp-Llm|Topic|Phasetransition Dataset|Topic|RELATED_TO
20|Ctp-Llm|Topic|Clinical Trial Outcome Prediction|Topic|RELATED_TO
20|Michael Reinisch|Author|Ctp-Llm|Topic|AUTHORED
20|Jianfeng He|Author|Ctp-Llm|Topic|AUTHORED
20|Chenxi Liao|Author|Ctp-Llm|Topic|AUTHORED
20|Sauleh Ahmad Siddiqui|Author|Ctp-Llm|Topic|AUTHORED
20|Bei Xiao|Author|Ctp-Llm|Topic|AUTHORED
21|Clinical Trial Outcome (Cto) Benchmark|Topic|Clinical Trials|Topic|RELATED_TO
21|Chufan Gao|Author|Clinical Trial Outcome (Cto) Benchmark|Topic|AUTHORED
21|Jathurshan Pradeepkumar|Author|Clinical Trial Outcome (Cto) Benchmark|Topic|AUTHORED
21|Trisha Das|Author|Clinical Trial Outcome (Cto) Benchmark|Topic|AUTHORED
21|Shivashankar Thati|Author|Clinical Trial Outcome (Cto) Benchmark|Topic|AUTHORED
21|Jimeng Sun|Author|Clinical Trial Outcome (Cto) Benchmark|Topic|AUTHORED
21|Drug Discovery And Development|Topic|Clinical Trials|Topic|RELATED_TO
22|Machine Learning|Topic|Clinical Domain|Topic|RELATED_TO
22|Data Scarcity|Topic|Clinical Trials|Topic|RELATED_TO
22|Ethical Considerations|Topic|Clinical Trials|Topic|RELATED_TO
22|Clinical Trials|Topic|Privacy Regulations|Topic|RELATED_TO
22|Clinical Trials|Topic|High Costs|Topic|RELATED_TO
22|Clinical Trials|Topic|Extended Duration|Topic|RELATED_TO
22|Large Language Models|Topic|Synthetic Clinical Trials|Topic|RELATED_TO
22|Retrieval-Reasoning Few-Shot Framework|Topic|Synthetic Clinical Trials|Topic|RELATED_TO
22|Synthetic Clinical Trials|Topic|Binary Success/Failure Labels|Topic|RELATED_TO
22|Clinicaltrials.Gov|Topic|Synthetic Data|Topic|RELATED_TO
22|Synthetic Data|Topic|Real Datasets|Topic|RELATED_TO
22|Pre-Trained Model|Topic|Binary Classifier|Topic|RELATED_TO
22|Binary Classifier|Topic|Trial Outcome Prediction|Topic|RELATED_TO
22|Zerui Xu|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
22|Fang Wu|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
22|Yuanyuan Zhang|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
22|Yue Zhao|Author|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Tianyang Wang|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Ming Liu|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Benji Peng|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Xinyuan Song|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Charles Zhang|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Xintian Sun|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Qian Niu|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Junyu Liu|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Silin Chen|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Keyu Chen|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Ming Li|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Pohsun Feng|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Ziqian Bi|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Yunze Wang|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Yichao Zhang|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Cheng Fei|Author|AUTHORED
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper|Lawrence Kq Yan|Author|AUTHORED
23|Clinical Trials|Topic|Drug Development|Topic|RELATED_TO
23|Phase I|Topic|Clinical Trials|Topic|RELATED_TO
23|Phase Ii|Topic|Clinical Trials|Topic|RELATED_TO
23|Phase Iii|Topic|Clinical Trials|Topic|RELATED_TO
23|Phase Iv|Topic|Clinical Trials|Topic|RELATED_TO
23|Challenges In Clinical Trials|Topic|Clinical Trials|Topic|RELATED_TO
23|Innovative Technologies|Topic|Clinical Trials|Topic|RELATED_TO
23|Emerging Therapies|Topic|Clinical Trials|Topic|RELATED_TO
23|Regulatory Reforms|Topic|Clinical Trials|Topic|RELATED_TO
23|Global Collaboration|Topic|Clinical Trials|Topic|RELATED_TO
24|Bayesian Adaptive Designs|Topic|Clinical Trials|Topic|RELATED_TO
24|Covid-19 Pandemic|Topic|Clinical Trials|Topic|RELATED_TO
24|Shirin Golchi|Author|Efficient Estimation And Uncertainty Quantification|Topic|AUTHORED
24|Efficient Estimation And Uncertainty Quantification|Topic|Design Operating Characteristics|Topic|RELATED_TO
24|Design Operating Characteristics|Topic|Ordinal Disease-Progression Scale Endpoint|Topic|RELATED_TO
24|Clinical Trial Design|Topic|Covid-19 Pandemic|Topic|RELATED_TO
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Zifeng Wang|Author|AUTHORED
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Chufan Gao|Author|AUTHORED
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Lucas M. Glass|Author|AUTHORED
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Jimeng Sun|Author|AUTHORED
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Clinical Simulation|Topic|RELATED_TO
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Individualized Predictive Modeling|Topic|RELATED_TO
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper|Computer-Aided Trial Design|Topic|RELATED_TO
26|Clinical Trial Outcome Prediction|Topic|Machine Learning Models|Topic|DISCUSSES
26|Clinical Trial Outcome Prediction|Topic|Clinical Trials|Topic|DISCUSSES
26|Clinical Trial Outcome Prediction|Topic|Drug Portfolio|Topic|DISCUSSES
26|Language Interaction Network (Lint)|Topic|Clinical Trial Outcome Prediction|Topic|RELATED_TO
26|Language Interaction Network (Lint)|Topic|Free-Text Descriptions|Topic|DISCUSSES
26|Language Interaction Network (Lint)|Topic|Roc-Auc Scores|Topic|DISCUSSES
26|Chufan Gao|Author|Language Interaction Network (Lint)|Topic|AUTHORED
26|Tianfan Fu|Author|Language Interaction Network (Lint)|Topic|AUTHORED
26|Jimeng Sun|Author|Language Interaction Network (Lint)|Topic|AUTHORED
26|Biologics|Topic|Clinical Trial Outcome Prediction|Topic|RELATED_TO
26|Small-Molecule Drugs|Topic|Clinical Trial Outcome Prediction|Topic|RELATED_TO
26|Graph Neural Networks|Topic|Biologics|Topic|DISCUSSES
26|Phases I, Ii, And Iii|Topic|Language Interaction Network (Lint)|Topic|RELATED_TO
27|Rats|Topic|Random Dot Motion Task|Topic|RELATED_TO
27|Random Dot Motion Task|Topic|Stimulus Integration|Topic|DISCUSSES
27|Rats|Topic|Trial Difficulty|Topic|RELATED_TO
27|Rats|Topic|Reward-Related Parameters|Topic|RELATED_TO
27|Pamela Reinagel|Author|Rats|Topic|AUTHORED
27|Emily Mankin|Author|Rats|Topic|AUTHORED
27|Adam Calhoun|Author|Rats|Topic|AUTHORED
28|Bayesian Trial Monitoring Scheme|Topic|Clinical Trials|Topic|RELATED_TO
28|Latent Gaussian Process (Lgp)|Topic|Discrete Longitudinal Data|Topic|RELATED_TO
28|Yanxun Xu|Author|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|AUTHORED
28|Yuan Ji|Author|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper|AUTHORED
28|Posterior Inference|Topic|Monte Carlo Algorithm|Topic|RELATED_TO
28|Simulation Studies|Topic|Clinical Scenarios|Topic|RELATED_TO
28|Case Study|Topic|Real-Life Trial|Topic|RELATED_TO
28|Trial Monitoring|Topic|Futility|Topic|RELATED_TO
28|Repeated Outcomes|Topic|Binary Outcomes|Topic|RELATED_TO
28|Posterior Consistency Property|Topic|Latent Gaussian Process (Lgp)|Topic|RELATED_TO
28|Observed Longitudinal Binary Outcomes|Topic|Latent Gaussian Process (Lgp)|Topic|RELATED_TO
28|Overall Trial Design|Topic|Sample Size|Topic|RELATED_TO
28|Overall Trial Design|Topic|Power Calculation|Topic|RELATED_TO
